Skip to content
DataLookout
Menu

SerF-ADJNCT07904156

A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Carcinoma

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

2-Year Recurrence-Free Survival (RFS) Rate
Timeframe: 2-year

Secondary (2)

Overall Survival (OS)
Incidence and Severity of Adverse Events

Arms and interventions

Serplulimab Plus FruquintinibExperimental

Participants will start adjuvant treatment within 12 weeks after surgery. Serplulimab 300 mg will be administered by intravenous infusion every 3 weeks for up to 17 cycles. Fruquintinib 5 mg will be taken orally once daily for 14 days, followed by 7 days off, for a total of 12 weeks.

ObservationNo intervention

Participants will receive no adjuvant study treatment after surgery. They will undergo scheduled clinical and imaging assessments every 12 weeks to monitor for disease recurrence and survival.

Drugs: Serplulimab + Fruquintinib